- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Day One Biopharmaceuticals announces R&D leadership change | 1 | Investing.com | ||
| Mi | Day One Biopharmaceuticals, Inc.: Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development | 2 | GlobeNewswire (USA) | ||
| Mi | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Di | CEO von Day One Biopharmaceuticals verkauft Aktien im Wert von 139.420 US-Dollar | 1 | Investing.com Deutsch | ||
| 05.11. | Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Upgraded by TD Cowen | 3 | MarketBeat | ||
| DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 30.10. | Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate Progress | 98 | GlobeNewswire (Europe) | Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call... ► Artikel lesen | |
| 30.10. | Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.10. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.10. | Day One Biopharma shares retain overweight rating on ojemda drug usage | 2 | Investing.com | ||
| 23.10. | Day One Biopharma-Aktien behalten Overweight-Rating aufgrund der Ojemda-Medikamentennutzung | 3 | Investing.com Deutsch | ||
| 16.10. | Day One Biopharmaceuticals, Inc.: Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 | 1 | GlobeNewswire (USA) | ||
| 09.10. | Day One Biopharmaceuticals stock target raised, holds buy on Ojemda outlook | 2 | Investing.com | ||
| 09.10. | Kursziel für Day One Biopharmaceuticals-Aktie angehoben, Kaufempfehlung aufgrund der Ojemda-Aussichten bestätigt | 2 | Investing.com Deutsch | ||
| 12.08. | Goldman Sachs maintains $45 target on Day One Biopharmaceuticals | 6 | Investing.com | ||
| 02.08. | Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.08. | Day One Biopharma draws double upgrade at BofA on Ojemda potential | 3 | Seeking Alpha | ||
| 30.07. | Day One Biopharmaceuticals GAAP EPS of -$0.05, revenue of $8.19M | 1 | Seeking Alpha | ||
| 30.07. | Day One Biopharmaceuticals, Inc.: Day One Reports Second Quarter 2024 Financial Results and Corporate Progress | 193 | GlobeNewswire (Europe) | Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch Expanded pipeline with DAY301, potential first-in-class Antibody Drug Conjugate (ADC) targeting... ► Artikel lesen | |
| 30.07. | Day One Biopharmaceuticals announces $175M private placement | 2 | Seeking Alpha | ||
| 30.07. | Day One Biopharmaceuticals, Inc.: Day One Announces Oversubscribed $175.0 Million Private Placement | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,000 | -0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 5,690 | -5,79 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,725 | -3,08 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,945 | 0,00 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| ARCTURUS THERAPEUTICS | 16,220 | +0,19 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,950 | 0,00 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,230 | -0,32 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,170 | -0,94 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| VIR BIOTECHNOLOGY | 6,650 | -1,34 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,545 | -0,11 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,000 | 0,00 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
| ARVINAS | 23,110 | +1,85 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
| BIO-PATH | 0,790 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2024 Financial Results | Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology... ► Artikel lesen |
Das Unternehmen DAY ONE BIOPHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,280 (-2,05 %) liegt der Kurs bei 13,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAY ONE BIOPHARMACEUTICALS INC finden Sie auf Wallstreet Online.
